Firefly Bio Acquired by Johnson & Johnson | Healthcare M&A Deal

Johnson & Johnson has acquired Firefly Bio, a healthcare services other business in the United States, for $1 billion. Firefly Bio develops healthcare services offerings focused on advancing biomedical research and translational capabilities, supporting clinical and commercial development needs. Johnson & Johnson acquisitions in healthcare M&A aim to strengthen its pipeline and expand capabilities through this strategic acquisition. The merger acquisition is announced and sized over $100M, reflecting a strategic acquisition by a corporate buyer rather than private equity.